Literature DB >> 17492598

Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial.

V H Tam1, A Louie, T R Fritsche, M Deziel, W Liu, D L Brown, L Deshpande, R Leary, R N Jones, G L Drusano.   

Abstract

We have shown previously in animal model and in vitro systems that antimicrobial therapy intensity has a profound influence on subpopulations of resistant organisms. Little attention has been paid to the effect of therapy duration on resistant subpopulations. We examined the influence of therapy intensity (area under the concentration/time curve for 24 h:minimum inhibitory concentration [AUC24:MIC] ratio) and therapy duration on resistance emergence using an in vitro model of Staphylococcus aureus infection. AUC24:MIC ratios of>or=100 were necessary to kill a substantial portion of the total population. Importantly, we demonstrated that therapy duration is a critical parameter. As the duration increased beyond 5 days, the intensity needed to suppress the antibiotic-resistant subpopulations increased, even when the initial bacterial kill was>4 log10 (cfu/mL). These findings were prospectively validated in an independent experiment in which exposures were calculated from the results of fitting a large mathematical model to all data simultaneously. All of the prospectively determined predictions were fulfilled in this validation experiment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17492598     DOI: 10.1086/518003

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  36 in total

1.  Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli.

Authors:  Renu Singh; Michelle C Swick; Kimberly R Ledesma; Zhen Yang; Ming Hu; Lynn Zechiedrich; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2012-01-09       Impact factor: 5.191

2.  The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression.

Authors:  Arnold Louie; Caroline Grasso; Nadzeya Bahniuk; Brian Van Scoy; David L Brown; Robert Kulawy; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2010-04-05       Impact factor: 5.191

Review 3.  An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.

Authors:  Jotam Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-10-11       Impact factor: 5.191

Review 4.  Mechanisms of resistance and clinical relevance of resistance to β-lactams, glycopeptides, and fluoroquinolones.

Authors:  Louis B Rice
Journal:  Mayo Clin Proc       Date:  2012-02       Impact factor: 7.616

Review 5.  Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1.

Authors:  G L Drusano; Arnold Louie; Alasdair MacGowan; William Hope
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

6.  Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis.

Authors:  Abdullah Alsultan; Guohua An; Charles A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2015-04-13       Impact factor: 5.191

7.  Resistance emergence mechanism and mechanism of resistance suppression by tobramycin for cefepime for Pseudomonas aeruginosa.

Authors:  G L Drusano; Robert A Bonomo; Nadzeya Bahniuk; Juergen B Bulitta; Brian Vanscoy; Holland Defiglio; Steven Fikes; David Brown; Sarah M Drawz; Robert Kulawy; Arnold Louie
Journal:  Antimicrob Agents Chemother       Date:  2011-10-17       Impact factor: 5.191

8.  Differing effects of combination chemotherapy with meropenem and tobramycin on cell kill and suppression of resistance of wild-type Pseudomonas aeruginosa PAO1 and its isogenic MexAB efflux pump-overexpressed mutant.

Authors:  G L Drusano; Weiguo Liu; Christine Fregeau; Robert Kulawy; Arnold Louie
Journal:  Antimicrob Agents Chemother       Date:  2009-03-16       Impact factor: 5.191

9.  Optimal Piperacillin-Tazobactam Dosing Strategies against Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae.

Authors:  Henrietta Abodakpi; Kai-Tai Chang; Song Gao; Ana María Sánchez-Díaz; Rafael Cantón; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

10.  In vitro pharmacodynamics of AZD5206 against Staphylococcus aureus.

Authors:  Vincent H Tam; Kai-Tai Chang; Zhen Yang; Joseph Newman; Ming Hu
Journal:  Antimicrob Agents Chemother       Date:  2012-12-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.